SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Glinoer D., Gershengorn M. C. & Robbins J. Thyroxine-binding globulin biosynthesis in isolated monkey hepatocytes. Biochim. Biophys. Acta 1976; 418: 23244.
  • 2
    Kaplan M. M. & Utiger D. Iodothyronine metabolism in rat liver homogenates. J. Clin. Invest. 1978; 61: 45971.
  • 3
    Goglia F., Liverini G., Lanni A., Iossa S. & Barletta A. The effect of thyroid state on respiratory activities of three rat liver mitochondrial fractions. Mol. Cell. Endocrinol. 1989; 62: 416.
  • 4
    Fagiuoli S. & Van Thiel D. H. The liver in endocrine disorders. In: RustgiV. K. & VanThielD. H., eds. The Liver in Systemic Disease. Raven Press, New York , 1993; 2857.
  • 5
    Babb R. R. Associations between diseases of the thyroid and the liver. Am. J. Gastroenterol. 1984; 79: 4213.
  • 6
    Salata R., Klein I. & Levey G. Thyroid hormone homeostasis and the liver. Semin. Liver Dis. 1985; 5: 2934.
  • 7
    Fong T. L., McHutchison J. G. & Reynolds T. B. Hyperthyroidism and hepatic dysfunction: A case series analysis. J. Clin. Gastroenterol. 1992; 14: 2404.
  • 8
    Huang M. J., Li K. L., Wei J. S., Wu S. S., Fan K. D. & Liaw Y. F. Sequential liver and bone biochemical changes in hyperthyroidism: Revisited by a prospective controlled follow-up study. Am. J. Gastroenterol. 1994; 89: 10716.
  • 9
    Shaffer J. M. Disease of the liver in hyperthyroidism. Arch. Pathol. 1940; 29: 2030.
  • 10
    Piper J. & Poulsen E. Liver biopsy in thyrotoxicosis. Acta Med. Scand. 1947; 127: 43947.
  • 11
    Movitt E. R., Gersti B. & Davis A. E. Needle liver biopsy in thyrotoxicosis. Arch. Intern. Med. 1953; 91: 72939.
  • 12
    Dooner H. P., Parada J., Aliage C. & Hoyl C. The liver in thyrotoxicosis. Arch. Intern. Med. 1967; 120: 2532.
  • 13
    Lorenz G. & Weng W. Bioptical liver changes in florid hyperthyreosis. Acta Hepato-Gastroenterol. 1975; 22: 225.
  • 14
    Sola J., Pardo-Mindan F. J., Zozaya J., Ouiroga J., Sangro B. & Prieto J. Liver changes in patients with hyperthyroidism. Liver 1991; 11: 1937.
  • 15
    Klion F. M., Segal R. & Schaffner F. The effect of altered thyroid function on the ultrastructure of the human liver. Am. J. Med. 1971; 50: 31724.
  • 16
    Myers J. D., Brannon E. S. & Holland B. C. A correlative study of the cardiac output and the hepatic circulation in hyperthyroidism. J. Clin. Invest. 1950; 29: 106977.
  • 17
    Chen F. W. Liver function in thyrotoxicosis. J. Formosan Med. Assoc. 1963; 62: 1309.
  • 18
    Greenberger W. J., Milligan F. D., DeGroot L. J. & Isselbacher K. J. Jaundice and thyrotoxicosis in the absence of congestive heart failure. Am. J. Med. 1964; 36: 8406.
  • 19
    Gerlach U., Paul L. & Latzel H. Isoenzymes of alkaline phosphatase in hyperthyroidism. Enzymol. Biol. Clin. 1970; 11: 2516.
  • 20
    Aashkar F. S., Miller R., Smoak W. M. & Gilson A. J. Liver disease in hyperthyroidism. South. Med. J. 1971; 64: 4625.
  • 21
    Thompson P., Boehm T., Strum D. & Wartofsky L. Abnormalities of liver function tests in thyrotoxicosis. Milit. Med. 1978; 143: 54851.
  • 22
    Cooper D. S., Kaplan M. M., Ridgway E. C., Maloof F. & Daniels G. H. Alkaline phosphatase isoenzyme patterns in hyperthyroidism. Ann. Intern. Med. 1979; 90: 1648.
  • 23
    Azizi F. γ-Glutamyl transpeptidase levels in thyroid disease. Arch. Intern. Med. 1982; 142: 7981.
  • 24
    Yao J. D. C., Gross J. B., Lundwig J. & Purnell D. C. Cholestatic jaundice in hyperthyroidism. Am. J. Med. 1989; 86: 61920.
  • 25
    Adams P. H., Jowsey J., Kelly P. J., Riggs B. L., Kinney V. R. & Jones J. D. Effects of hyperthyroidism on bone and mineral metabolism in man. Q. J. Med. 1967; 36: 115.
  • 26
    Mosekilde L., Melsen F., Bagger J. P., Myhre-Jensen O. & Sorensen N. S. Bone changes in hyperthyroidism: Interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism. Acta Endocrinol. 1977; 85: 51525.
  • 27
    Klein I. & Levey G. S. Unusual manifestation of hypothyroidism. Arch. Intern. Med. 1984; 144: 1248.
  • 28
    Baker A., Kaplan M. M. & Wolfe H. Central congestive fibrosis of the liver in myxedema ascites. Ann. Intern. Med. 1972; 77: 927.
  • 29
    Domschke W. & Domschke S. Bilirubin metabolism and bile secretion: Hormonal regulation. In: BiancheL., GerokW. & SickingerK., eds, Liver and Bile. Falk Symposium MTP Press, Lancaster , UK , 1977.
  • 30
    Golding P., Smith M. & Williams R. Multisystem involvement in chronic liver disease. Am. J. Med. 1973; 55: 77282.
  • 31
    Schussler G. C., Schaffner F. & Korn F. Increased serum thyroid hormone binding and decreased free hormone in chronic active liver disease. N. Engl. J. Med. 1978; 299: 51015.
  • 32
    Crowe J. P., Christensen E., Butler J. et al. Primary biliary cirrhosis: The prevalence of hypothyroidism and its relationship to thyroid autoantibodies and sicca syndrome. Gastroenterology 1980; 78: 143741.
  • 33
    Elta G. H., Sepersky R. A., Goldberg M. J., Connors C. M., Miller K. B. & Kaplan M. M. Increased incidence of hypothyroidism in primary biliary cirrhosis. Dig. Dis. Sci. 1982; 28: 9715.
  • 34
    Thompson N. P., Leader S., Jamieson C. P., Burnham W. R. & Burroughs A. K. Reversible jaundice in primary biliary cirrhosis due to hypothyroidism. Gastroenterology 1994; 106: 13423.
  • 35
    Pateron D., Hartmann D. J., Duclos-Vallee J. C., Jouanolle H. & Beaugrand M. Latent autoimmune thyroid disease in patients with chronic HCV hepatitis. J. Hepatol. 1993; 17: 41719.
  • 36
    Tran A., Quaranta J. F., Benzaken S. et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 1993; 18: 2537.
  • 37
    Pawlotsky J. M., Yahia M. B., Andre C. et al. Immunological disorders in C virus chronic active hepatitis: A prospective case-control study. Hepatology 1994; 19: 8418.
  • 38
    Huang M. J., Wu S. S. & Liaw Y. F. Thyroid abnormalities in patients with chronic viral hepatitis. Hepatology 1994; 20: 16512.
  • 39
    Chopra I. J., Solomon D. H., Chopra U., Young R. T. & Chua Teco G. N. Alterations in circulating thyroid hormones and thyrotropin in hepatic cirrhosis: Evidence for euthyroidism despite subnormal serum triodothyronine. J. Clin. Endocrinol. Metab. 1974; 39: 50111.
  • 40
    Nomura S., Pittman C. S., Chambers J. B. Jr, Buck M. W. & Shimizu T. Reduced peripheral conversion of thyroxine to triiodothyronine in patients with hepatic cirrhosis. J. Clin. Invest. 1975; 56: 64352.
  • 41
    Green J. R. B., Snitcher E. J., Mowat N. A. G., Ekins R. P., Rees L. H. & Dawson A. M. Thyroid function and thyroid regulation in euthyroid men with chronic liver disease. Clin. Endocrinol. 1977; 7: 45361.
  • 42
    Hepner G. W. & Chopra I. J. Serum thyroid hormone levels in patients with liver diaease. Arch. Intern. Med. 1979; 139: 111720.
  • 43
    Walfish P. G., Orrego H., Israel Y., Blake J. & Kalant H. Serum triiodothyronine and other clinical and laboratory indices of alcoholic liver disease. Ann. Intern. Med. 1979; 91: 1316.
  • 44
    L'Age M., Meinhold H., Wenzel K. W. & Schleusener H. Relations between serum levels of TSH, TBG, T4, T3, γT3 and various histologically classified chronic liver diseases. J. Endocrinol. Invest. 1980; 4: 37983.
  • 45
    Gardner D. F., Carithers R. L. & Utiger R. D. Thyroid function tests in patients with acute and resolved hepatitis B virus infection. Ann. Intern. Med. 1982; 96: 4502.
  • 46
    Ross D. S., Daniels G. M., Dienstag D. L. & Ridgway E. C. Elevated thyroxine levles due to increased thyroxine- binding globulin in acute hepatitis. Am. J. Med. 1983; 74: 5649.
  • 47
    Borzio M., Caldara R., Borzio F., Piepoli V., Rampini P. & Ferrari C. Thyroid function tests in chronic liver disease: Evidence for multiple abnormalities despite clinical euthyroidism. Gut 1983; 24: 6316.
  • 48
    Itoh S., Yamaba Y., Oda T. & Kawagoe K. Serum thyroid hormone, triiodothyronine, thyroxine, and triiodothyronine/thyroxine ratio in patients with fulminant, acute and chronic hepatitis. Am. J. Gastroenterol. 1986; 81: 4449.
  • 49
    Kalk W. J., Kew M. C., Danilewitz M. D., Jacks F., Van der Walt L. A. & Levin J. Thyroxine-binding globulin and thyroid function tests in patients with hepatocellular carcinoma. Hepatology 1982; 2: 726.
  • 50
    Liewendahl K., Helenius T., Tanner P. & Salaspuro M. Serum-free thyroid hormone concentrations and indices in alcoholic liver cirrhosis, primary biliary cirrhosis and chronic active hepatitis. Acta Endocrinol. (Suppl.) 1983; 251: 216.
  • 51
    Murata Y., Sarne D. H., Horwitz A. L. et al. Characterization of thyroxine-binding globulin secreted by a human hepatoma cell line. J. Clin. Endocrinol. Metab. 1985; 60: 4728.
  • 52
    Terui S., Meriya Y., Yamamoto H. & Koyama Y. Thyroxine-binding globulin as a marker of liver tumors. Cancer Detect. Prev. 1987; 10: 3718.
  • 53
    Alexopoulos A., Hutchins W., Bari A., Keating P. J., Johnson P. J. & Williams R. Hyperthyroxinaemia in hepatocellular carcinoma: Relation to thyroid-binding globulin in the clinical and preclinical stages of the diseases. Br. J. Cancer 1988; 57: 31316.
  • 54
    Becker U., Gluud C. & Bennett P. Thyroid hormones and thyroxine-binding globulin in relation to liver function and serum testosterone in men with alcoholic cirrhosis. Acta Med. Scand. 1988; 224: 36773.
  • 55
    Huang M. J. & Liaw Y. F. Changes in thyroid hormone concentration in liver disease. J. Formosan Med. Assoc. 1989; 88: 5279.
  • 56
    Huang M. J. & Liaw Y. F. Thyroxine-binding globulin in patients with chronic hepatitis B virus infection: Different implications in hepatitis and hepatocellular carcinoma. Am. J. Gastroenterol. 1990; 85: 2814.
  • 57
    Chopra I. J., Williams D. E., Orgiazzi J. & Solomon D. H. Opposite effects of dexamethasone on serum concentrations of 3,3′,5-triodothyronine. J. Clin. Endocrinol. Metab. 1975; 41: 91120.
  • 58
    Cooper D. S., Daniels G. H., Ladenson P. W. & Ridgway E. C. Hyperthyroxinemia in patients treated with high dose propranolol. Am. J. Med. 1982; 73: 86771.
  • 59
    Felicetta J. V., Green W. L. & Melp W. B. Inhibition of hepatic binding of thyroxine by cholecystographic agents. J. Clin. Invest. 1980; 65: 103240.
  • 60
    Zimmerman H. J. Hormonal derivatives and other drugs used to treat endocrine disease. In: ZimmermanH. J., ed., Hepatotoxicity. Appleton-Century-Crofts, New York , 1978; 45960.
  • 61
    Vitug A. C. & Goldman J. M. Hepatoxicity from antithyroid drugs. Hormone Res. 1985; 21: 22934.
  • 62
    Mihas A. A., Holley P., Koff R. S. & Hirschowitz B. I. Fulminant hepatitis and lymphocyte sensitization due to propylthiouracil. Gastroenterology 1976; 70: 7704.
  • 63
    Limaye A. & Ruffolo R. Propythiouracil-induced fatal hepatic necrosis. Am. J. Gastroenterol. 1978; 82: 1524.
  • 64
    Jonas M. M. & Eidon M. S. Propylthiouracil hepatotoxicity: Two pediatric cases and review of the literature. J. Pediatr. Gastroenterol. Nutr. 1988; 7: 7769.
  • 65
    Liaw Y. F., Huang M. J., Fan K. D., Li K. L., Wu S. S. & Chen T. J. Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism: A cohort study. Ann. Intern. Med. 1993; 118: 4248.
  • 66
    Hunter A. L. & Neal R. A. Inhibition of hepatic mixed-function oxidase activity in vitro and in vivo by various thiono-sulfur-containing compounds. Biochem. Pharmac. 1975; 24: 2199205.
  • 67
    Israel Y., Kalant H., Orrego H. et al. Experimental alcoholic induced hepatic necrosis: Suppression by propylthiouracil. Proc. Natl Acad. Sci. USA 1975; 72: 113741.
  • 68
    Isarael Y., Walfish P. G., Orrego H., Blake J. & Kalant H. Thyroid hormones in alcoholic liver disease: Effect of treatment with 6-n-propylthiouracil. Gastro-enterology 1979; 76: 11622.
  • 69
    Orrego H., Kalant H., Israel Y. et al. Effect of shortterm therapy with propylthiouracil in patients with alcoholic liver diseases. Gastroenterology 1979; 76: 10515.
  • 70
    Orrego H., Blake J. E., Blendis L. M., Compton K. V. & Isarael Y. Long-term treatment of alcoholic liver disease with propylthiouracil. N. Engl. J. Med. 1987; 317: 14217.
  • 71
    Halle P., Pare P., Kaptein E., Kanel G., Redeker A. G. & Reynolds T. B. Double-blind controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology 1982; 82: 92931.
  • 72
    Pierugues R., Blanc P., Barneon C., Bories P. & Michel H. Short-term therapy with propylthiouracil for alcoholic hepatitis: A clinical, biochemical and histological randomizied trial about 25 patients. Gastroenterology 1989; 96: A644.
  • 73
    Mayet W. J., Hess G., Gerken G. et al. Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology 1989; 10: 249.
  • 74
    Schultz M., Muller R., Von zur Muhlan A. & Brabant G. Induction of hyperthyroidism by interferon- alpha. Lancet 1989; 1: 1452.
  • 75
    Berris B. & Feinman V. Thyroid dysfunction and liver injury following alpha-interferon treatment of chronic viral hepatitis. Dig. Dis. Sci. 1991; 36: 165760.
  • 76
    Lisker-Melman M., DiBiceglie A. M., Usala S. J., Weintraub B., Murray L. M. & Hoofnagle J. H. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 1992; 102: 211560.
  • 77
    Chuang Y. H. & Shong Y. K. Development of thyroid autoimmunity after administration of recombinant human interferon-a-2b for chronic viral hepatitis. Am. J. Gastroenterol. 1993; 88: 2447.
  • 78
    Fentimann I. S., Balkwill F. R., Thomas B. S., Russel M. J., Todd I. & Bottazzo G. F. An autoimmune aetiology or hypothyroidism following interferon therapy for breast cancer. Eur. J. Cancer Clin. Oncol. 1988; 8: 1299303.
  • 79
    Ronnblom L. E., Alm G. V. & Oberg K. E. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann. Intern. Med. 1991; 115: 17883.